Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Importantly, tirzepatide carries a boxed warning for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
This triple mechanism distinguishes it from existing approved treatments such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GIP/GLP-1 agonist)
The autoimmune signal still exists
Compounded versions are typically 6085% less expensive than brand-name alternatives and are legally available when the FDA has confirmed a shortage of the branded product
Dotson CD, Shaw HL, Mitchell BD, Munger SD, Steinle NI
US$ 24.70
US$ 23.75
US$ 24.16
US$ 24.47
US$ 22.09
US$ 29.36
US$ 22.36
